GB Sciences' CEO John Poss and Chief Science Officer Dr. Andrea Small-Howard Featured at Digital Hollywood's California Cannabis Forum in Los Angeles
Mr. Poss will speak on GB Sciences' collaboration with Native Americans in California; Dr. Small-Howard will discuss research to address specific diseases using cannabinoids.
LAS VEGAS, Oct. 10, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) announces that CEO John Poss and Chief Science Officer Dr. Andrea Small-Howard will be featured on panels at the Digital Hollywood's California Cannabis Forum at the Skirball Center in Los Angeles.
On October 17th, Dr. Small-Howard will be joined by biopharma research leaders from Phylos Bioscience and Tilray to discuss GB Sciences' groundbreaking innovations in treating neurological disorders, inflammatory disorders, cardiovascular disease, and chronic pain. In addition, Dr. Small-Howard will speak to the company's global research footprint, including a new collaboration with the National Kapodistrian University of Athens, Greece to use cultivar analysis to determine treatment applications.
On October 18th, Mr. Poss will speak to GB Sciences' collaboration with the Los Coyotes Band of Cahuilla & Cupeño Indians, a federally recognized tribe whose 25,000 acre reservation is located in San Diego County. In 2017, GB Sciences and Los Coyotes signed a memorandum of understanding to co-develop cultivation and manufacturing operations on tribal land. Mr. Poss will be joined by tribal leaders from the California Native American Cannabis Association (CNACA) to discuss the opportunities and challenges facing California's tribes in the cannabis market.
Their participation, which follows on Dr. Small-Howard's panel at September's "State of Cannabis" conference in Long Beach, reflects increased GB Sciences visibility and recognition in the California cannabis market.
Digital Hollywood debuted in 1994 and is among the leading entertainment trade conferences; and debuted its Cannabis Forum last year, following adult use legalization. Over 15,000 top executives in the film, television, music, technology and cannabis industries attend Digital Hollywood events annually.
Panel details are below:
Wednesday, October 17
1:45 PM – 2:45 PM
The Science of Medical Cannabis: Matching Strains, Potency and
Dosage to Specific Diseases and Disorders
Dr. Andrea Small-Howard, Chief Science Officer, GB Sciences
(GBS)
Jessica Assaf, Founder, Cannabis Feminist, co-founder,
Hempia
Tim Blake, Founder and Producer, The Emerald Cup
Dr. Catherine Jacobson, Director of Clinical Research,
Tilray
Sundarajan Mutialu, Chief Technology Officer and Co-CEO,
AZENTIVE
Mowgli Holmes, PhD, co-founder, CEO, Phylos
Bioscience
David Traub, Co-Founder, Epiphany Film Fund, Moderator
Thursday, October 18
The Luncheon at Skirball Center
12:15 PM - 1:45 PM
Native American Leadership in the Cannabis Industry
Tina Braithwaite, former, Chairwoman, Benton Paiute
Tribe
John Poss, CEO, GB Sciences
David Vilapondo, Executive Director, Ilpay Nation, Santa
Ysabel Tribal Cannabis Regulatory Agency and Interim Executive
Director, California Native American Cannabis Association
(CNACA)
Cameron Keluche, President and CEO, KelSie
Biotech
Moderator - Amanda Chicago Lewis, Columnist, Rolling Stone
Event registration can be found here:
http://www.digitalhollywood.com/CannabisForumFl18.html
About GB Sciences, Inc.
GB Sciences,
Inc. (GBLX) is a diverse cannabis company,
focused on standardized cultivation and production methods; as well
as biopharmaceutical research and development. The Company's goal
is creating safe, standardized, pharmaceutical-grade, cannabinoid
therapies that target a variety of medical conditions. To learn
more about GB Sciences, Inc., go to: http://gbsciences.com.
Forward-Looking Statements
This press
release may contain statements relating to future results or
events, which are forward-looking statements. Words such as
"expects", "intends", "plans", "may", "could", "should",
"anticipates", "likely", "believes" and words of similar import may
identify forward-looking statements. These statements are not
historical facts, but instead represent only the Company's belief
regarding future events, many of which, by their nature, are
inherently uncertain and outside of the Company's control. It
is possible that the Company's actual results and financial
condition may differ, possibly materially, from the anticipated
results and financial condition indicated in these forward-looking
statements. Further, information concerning the Company and
its business, including factors that potentially could materially
affect the Company's business and financial and other results, are
contained in the Company's filings with the Securities and Exchange
Commission, available at www.sec.gov. All
forward-looking statements included in this press release are made
only as of the date of this press release, and we do not undertake
any obligation to publicly update or correct any forward-looking
statements to reflect events or circumstances that subsequently
occur or of which we hereafter become aware.
Note: Although the Company's research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.
Contact Information
Corporate:
GB Sciences, Inc., 3550 West Teco Ave., Las Vegas, NV
89118
866-721-0297, or
Tom Arcuragi, EVP, [email protected]
View original content to download multimedia:http://www.prnewswire.com/news-releases/gb-sciences-ceo-john-poss-and-chief-science-officer-dr-andrea-small-howard-featured-at-digital-hollywoods-california-cannabis-forum-in-los-angeles-300728285.html